WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2022)
Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Consensus
Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
LNTH
LANTHEUS HOLDINGS INC
$3.68B$53.51$107.25100.43%Strong Buy410.81%38.72%N/AN/A
SHC
SOTERA HEALTH CO
$2.41B$8.56$13.5658.36%Hold105.55%56.64%57.19%12.35%
SYNH
SYNEOS HEALTH INC
$3.56B$34.57$52.2951.25%Buy94.82%24.24%19.33%7.91%
QDEL
QUIDELORTHO CORP
$6.32B$95.67$106.0010.80%Buy5-8.68%N/AN/AN/A
FLGT
FULGENT GENETICS INC
$992.06M$33.70$65.0092.88%Buy4-22.21%-59.11%-1.77%-1.61%
CODX
CO-DIAGNOSTICS INC
$85.95M$2.78$5.5097.84%Buy2-18.32%-81.63%6.19%5.65%
TWST
TWIST BIOSCIENCE CORP
$1.49B$26.33$35.3334.19%Buy327.55%N/A-26.80%-22.01%
DXCM
DEXCOM INC
$47.38B$122.67$266.07116.90%Strong Buy1413.78%34.11%35.57%13.25%
BWAY
BRAINSWAY LTD
$29.56M$1.76$9.94464.66%Strong Buy419.01%N/A21.98%15.89%
DMTK
DERMTECH INC
$71.00M$2.35$11.33382.26%Strong Buy480.34%N/A-34.12%-27.25%
A
AGILENT TECHNOLOGIES INC
$46.27B$156.28$152.67-2.31%Buy97.50%16.61%34.95%16.97%
PHG
KONINKLIJKE PHILIPS NV
$12.17B$13.98N/AN/ABuy32.45%-20.01%13.10%6.11%
QGEN
QIAGEN NV
$11.20B$49.19$57.5016.89%Buy2-0.57%2.38%18.06%9.22%
DRIO
DARIOHEALTH CORP
$100.18M$4.30$12.17182.95%Strong Buy318.47%N/A28.29%19.92%
SERA
SERA PROGNOSTICS INC
$39.08M$1.26$8.50574.60%Buy3655.36%N/AN/AN/A
NEOG
NEOGEN CORP
$1.67B$15.53$14.00-9.85%Buy210.28%32.37%10.25%9.27%
MEDP
MEDPACE HOLDINGS INC
$6.53B$209.86$217.003.40%Hold39.04%1.85%77.78%20.48%
CDNA
CAREDX INC
$680.46M$12.71$36.00183.24%Strong Buy48.24%N/A-6.50%-5.21%
ICLR
ICON PLC
$16.19B$198.49$258.3030.13%Buy105.67%35.97%16.62%7.99%
TMO
THERMO FISHER SCIENTIFIC INC
$222.75B$567.95$614.258.15%Buy80.45%17.07%24.39%11.73%
CSTL
CASTLE BIOSCIENCES INC
$643.24M$24.41$53.00117.12%Strong Buy614.45%N/A-13.90%-12.49%
DGX
QUEST DIAGNOSTICS INC
$17.14B$150.50$146.50-2.66%Hold12-5.20%-7.85%16.11%7.60%
SENS
SENSEONICS HOLDINGS INC
$535.65M$1.12$3.00167.86%Buy192.94%N/AN/A-15.71%
LHDX
LUCIRA HEALTH INC
$11.45M$0.28$3.501,141.13%Hold335.86%N/A138.69%44.64%
BNGO
BIONANO GENOMICS INC
$641.36M$2.16$9.50339.81%Strong Buy237.67%N/A-52.69%-45.86%
LH
LABORATORY CORP OF AMERICA HOLDINGS
$20.88B$235.68$296.5625.83%Strong Buy90.36%0.70%17.54%8.93%
DHR
DANAHER CORP
$197.87B$271.82$312.4014.93%Strong Buy110.79%8.56%18.08%10.48%
MXCT
MAXCYTE INC
$572.48M$5.61$11.0096.08%Strong Buy118.78%N/A-8.42%-7.48%
GENE
GENETIC TECHNOLOGIES LTD
$21.05M$1.14N/AN/AN/AN/AN/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$35.49B$428.54$473.1310.40%Strong Buy86.21%11.85%211.22%38.08%
NRC
NATIONAL RESEARCH CORP
$964.44M$39.06N/AN/AN/AN/AN/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$19.10M$3.28$2.00-39.02%Strong Buy2N/AN/A-1.30%-1.18%
BNR
BURNING ROCK BIOTECH LTD
$306.54M$2.95$9.75230.51%Strong Buy324.26%N/A-43.71%-32.80%
WAT
WATERS CORP
$20.38B$343.04$338.33-1.37%Hold62.40%6.90%224.84%28.21%
MOTS
MOTUS GI HOLDINGS INC
$5.59M$1.20$8.00566.67%Strong Buy2115.93%N/A-336.03%-14.74%
HSKA
HESKA CORP
$718.49M$66.37$142.25114.33%Strong Buy49.94%N/A3.29%2.35%
BIOC
BIOCEPT INC
$11.51M$0.68$8.001,085.19%Strong Buy2-39.39%N/A-50.21%-27.04%
RNLX
RENALYTIX PLC
$74.89M$2.00$6.67233.35%Strong Buy3253.91%N/A-226.55%-110.27%
PRPO
PRECIPIO INC
$16.52M$0.72$4.00452.49%Strong Buy1N/AN/AN/AN/A
STIM
NEURONETICS INC
$168.77M$6.20$10.0061.29%Buy47.66%N/A-37.16%-19.63%
PSNL
PERSONALIS INC
$114.47M$2.49$10.00301.61%Buy319.45%N/A-37.36%-28.49%
MYGN
MYRIAD GENETICS INC
$1.58B$19.49$23.5020.57%Hold23.99%N/AN/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$46.04M$0.37$3.00710.81%Strong Buy1103.79%N/A-456.46%-213.11%
ME
23ANDME HOLDING CO
$1.40B$3.08$5.5078.57%Buy4N/AN/AN/AN/A
IQV
IQVIA HOLDINGS INC
$39.08B$210.41$249.0718.37%Strong Buy147.07%24.34%49.40%10.90%
ONVO
ORGANOVO HOLDINGS INC
$14.29M$1.64N/AN/AN/AN/AN/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$10.69B$210.07$302.3343.92%Strong Buy137.42%18.62%30.53%10.86%
MTD
METTLER TOLEDO INTERNATIONAL INC
$33.06B$1,482.73$1.38k-7.09%Buy52.89%7.87%-1,302.24%32.73%
MYNZ
MAINZ BIOMED NV
$117.75M$8.13$20.00146.00%Strong Buy277.57%N/A-99.92%-86.01%
CNTG
CENTOGENE NV
$19.50M$0.72$4.25490.28%Buy2-61.31%N/A-120.95%-36.46%
OPGN
OPGEN INC
$6.44M$0.12$3.002,400.00%Buy157.37%N/A-165.66%-70.06%
VIVO
MERIDIAN BIOSCIENCE INC
$1.38B$31.59$34.007.63%Hold1N/AN/A10.36%8.23%
OLK
OLINK HOLDING AB (PUBL)
$2.68B$22.52$20.00-11.19%Hold329.29%N/A1.57%1.36%
AXDX
ACCELERATE DIAGNOSTICS INC
$74.92M$0.76$5.00561.38%Hold133.71%N/AN/AN/A
XGN
EXAGEN INC
$41.94M$2.57$10.33302.06%Strong Buy311.68%N/A-39.21%-21.68%
ISPC
ISPECIMEN INC
$12.18M$1.39$12.13772.30%Strong Buy2N/AN/AN/AN/A
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA INC
$2.25B$9.95$10.758.04%Buy215.99%N/A-32.84%-11.31%
ANIX
ANIXA BIOSCIENCES INC
$141.66M$4.62$11.00138.10%Strong Buy1N/AN/AN/AN/A
BVS
BIOVENTUS INC
$206.01M$2.65$3.7541.51%Hold59.60%N/A31.24%7.67%
NTRA
NATERA INC
$3.78B$38.76$78.17101.67%Strong Buy616.27%N/A-85.02%-30.47%
PKI
PERKINELMER INC
$17.93B$141.94$167.4017.94%Hold10-2.95%18.78%12.35%6.31%
HTGM
HTG MOLECULAR DIAGNOSTICS INC
$2.74M$0.25$2.50908.06%Buy216.55%N/A-777.28%-69.01%
NEO
NEOGENOMICS INC
$1.52B$12.07$19.1458.60%Buy97.44%N/A-1.99%-1.15%
BMRA
BIOMERICA INC
$51.63M$3.85$13.00238.13%Buy1N/AN/AN/AN/A
CEMI
CHEMBIO DIAGNOSTICS INC
$10.87M$0.30N/AN/AHold1N/AN/A-262.01%-74.98%
RDNT
RADNET INC
$1.17B$20.42$40.0095.89%Buy22.77%89.61%9.71%1.35%
NOTV
INOTIV INC
$140.25M$5.48$17.00210.22%Buy2N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$1.04B$1.35$4.00196.30%Buy2-4.89%N/A0.95%0.69%
EXAS
EXACT SCIENCES CORP
$8.17B$45.96$67.2046.21%Buy117.40%N/A-12.92%-6.37%
SQL
SEQLL INC
$4.72M$0.40$3.00655.67%Strong Buy1N/AN/AN/AN/A
PMD
PSYCHEMEDICS CORP
$31.33M$5.55N/AN/AN/AN/AN/AN/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$11.31M$0.18$5.002,693.30%Buy1N/AN/A-80.49%-66.54%
GH
GUARDANT HEALTH INC
$4.85B$47.35$85.8981.39%Strong Buy920.44%N/A-310.24%-30.40%
SLNO
SOLENO THERAPEUTICS INC
$7.43M$0.91$29.993,195.05%Strong Buy1N/AN/A128.83%61.24%
GTH
GENETRON HOLDINGS LTD
$95.50M$1.03$10.00870.87%Strong Buy1N/AN/AN/AN/A
CELC
CELCUITY INC
$147.49M$9.54$25.00162.05%Buy1N/AN/A-100.16%-66.77%
CDIO
CARDIO DIAGNOSTICS HOLDINGS INC
$17.59M$1.85N/AN/AN/AN/AN/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$103.88M$1.31$10.00663.36%Strong Buy1N/AN/AN/AN/A
AKU
AKUMIN INC
$92.35M$1.03$3.00191.26%Buy12.51%N/AN/A-3.47%
BIAF
BIOAFFINITY TECHNOLOGIES INC
$21.34M$2.55N/AN/AN/AN/AN/AN/AN/AN/A
ILMN
ILLUMINA INC
$33.10B$210.42$260.1823.65%Buy119.60%N/A13.58%8.12%
SRDX
SURMODICS INC
$501.79M$35.74$46.0028.71%Buy114.92%N/A-1.42%-0.98%
QTNT
QUOTIENT LTD
$2.12M$0.60$2.25275.00%Strong Buy220.79%N/AN/A-0.88%
MDXH
MDXHEALTH SA
$109.96M$7.05$16.50134.04%Strong Buy2N/AN/A-429.73%-218.59%
PRE
PRENETICS GLOBAL LTD
$204.65M$1.84$15.00713.45%Strong Buy1N/AN/A-2.14%-1.65%
VNRX
VOLITIONRX LTD
$115.62M$2.01$5.50173.63%Strong Buy2N/AN/AN/AN/A
BDSX
BIODESIX INC
$59.77M$1.42N/AN/ABuy120.57%N/AN/A-30.64%
ENZ
ENZO BIOCHEM INC
$91.59M$1.88N/AN/AN/AN/AN/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$26.75M$1.28N/AN/AN/AN/AN/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$10.98M$1.50N/AN/AHold2N/AN/AN/AN/A
NVTA
INVITAE CORP
$599.95M$2.47$5.15108.50%Sell82.79%N/A-201.82%-15.82%
LMDX
LUMIRADX LTD
$325.72M$1.07$7.17569.81%Strong Buy3-5.25%N/AN/A-22.48%
OABI
OMNIAB INC
$399.83M$3.60$9.00150.00%Strong Buy2N/AN/AN/AN/A
VRAX
VIRAX BIOLABS GROUP LTD
$13.65M$1.20N/AN/AN/AN/AN/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2022?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Lantheus Holdings (NASDAQ:LNTH)


Lantheus Holdings (NASDAQ:LNTH) is the top diagnostic & research stock with a Zen Score of 59, which is 28 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock return 89.35% over the past year, overperforming other diagnostic & research stocks by 116 percentage points.

Lantheus Holdings has an average 1 year price target of $107.25, an upside of 100.43% from Lantheus Holdings's current stock price of $53.51.

Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Lantheus Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the second best diagnostic & research stock with a Zen Score of 58, which is 27 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -62.11% over the past year, underperforming other diagnostic & research stocks by -36 percentage points.

Sotera Health Co has an average 1 year price target of $13.56, an upside of 58.36% from Sotera Health Co's current stock price of $8.56.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 20% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 30% have issued a Strong Sell.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third best diagnostic & research stock with a Zen Score of 56, which is 25 points higher than the diagnostic & research industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -66.13% over the past year, underperforming other diagnostic & research stocks by -40 percentage points.

Syneos Health has an average 1 year price target of $52.29, an upside of 51.25% from Syneos Health's current stock price of $34.57.

Syneos Health stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Koninklijke Philips Nv (NYSE:PHG)


Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.9%, which is 5 percentage points higher than the diagnostic & research industry average of 1.96%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

2. Psychemedics (NASDAQ:PMD)


Psychemedics (NASDAQ:PMD) has an annual dividend yield of 4.68%, which is 3 percentage points higher than the diagnostic & research industry average of 1.96%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -52.8% indicates that its high dividend yield might not be sustainable for the long-term.

3. National Research (NASDAQ:NRC)


National Research (NASDAQ:NRC) has an annual dividend yield of 2.15%, which is the same as the diagnostic & research industry average of 1.96%. National Research's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. National Research's dividend has shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 60.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 1.22% in the last day, and down -1.96% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 52 points higher than the diagnostic & research industry average of 34. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -62.11% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Quidelortho (NASDAQ:QDEL)


Quidelortho (NASDAQ:QDEL) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 52 points higher than the diagnostic & research industry average of 34. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -32.93% in the past year. It has underperformed other stocks in the diagnostic & research industry by -7 percentage points.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 52 points higher than the diagnostic & research industry average of 34. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -66.13% in the past year. It has underperformed other stocks in the diagnostic & research industry by -40 percentage points.

Are diagnostic & research stocks a good buy now?

44.71% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 20.47% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 37.24x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.